

Review

Open Access

Intrauterine infection/inflammation during pregnancy and offspring brain damages: Possible mechanisms involved

Mahmoud Huleihel*¹, Hava Golan^{1,2} and Mordechai Hallak^{1,3}

Address: ¹Department of Microbiology and Immunology and the BGU Cancer Research Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ²Department of Development and Zlotowski Center for Neuroscience, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel and ³Department of Obstetrics & Gynecology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Email: Mahmoud Huleihel* - huleihel@bgumail.bgu.ac.il; Hava Golan - havag@bgumail.bgu.ac.il;

Mordechai Hallak - hallakm@bgumail.bgu.ac.il

* Corresponding author

Published: 22 April 2004

Reproductive Biology and Endocrinology 2004, **2**:17

This article is available from: <http://www.rbej.com/content/2/1/17>

Received: 21 January 2004

Accepted: 22 April 2004

© 2004 Huleihel et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Intrauterine infection is considered as one of the major maternal insults during pregnancy. Intrauterine infection during pregnancy could lead to brain damage of the developmental fetus and offspring. Effects on the fetal, newborn, and adult central nervous system (CNS) may include signs of neurological problems, developmental abnormalities and delays, and intellectual deficits. However, the mechanisms or pathophysiology that leads to permanent brain damage during development are complex and not fully understood. This damage may affect morphogenic and behavioral phenotypes of the developed offspring, and that mice brain damage could be mediated through a final common pathway, which includes over-stimulation of excitatory amino acid receptor, over-production of vascularization/angiogenesis, pro-inflammatory cytokines, neurotrophic factors and apoptotic-inducing factors.

Maternal insults during pregnancy

Several maternal insults during pregnancy are known as major cause of fetal brain damage, including infection [1-3]. Maternal insult was associated with morbidity and mortality to infants, increased risk of intraventricular hemorrhage, neonatal white matter damage, and subsequent cerebral palsy. The susceptibility of the immature CNS to maternal insult is largely dependent on the temporal and regional status of critical developmental processes, as well as on the regulation of cerebral blood flow and metabolism. It was suggested that brain damage of offspring, which belong to mothers who have suffered of intrauterine infection/inflammation during pregnancy, is mediated by neurotoxicity (2-4). The mechanisms or pathophysiology of fetal neurotoxicity, induced by insult exposure are complex and not fully understood. It is pos-

sible that intrauterine infection/inflammation is mediated by factors that affect a final common pathway leading to neuronal injury, such as initiation of apoptosis, cellular dysfunction and death [1,2].

Systemic maternal infection and offspring brain damage

Clinical chorioamnionitis is considered as an infection of the uterus and its contents during pregnancy. The incidence varies between 10%-20%. According to histological examination it is affected 20% of term as compared to 60% of the preterm deliveries. It was shown that clinical and histopathological evidence of placental infection were associated with an elevated risk of unexplained cerebral palsy (CP) [odds ratio (OR) 9.3, 95% confidence interval (CI) 2.7, 31 for clinical chorioamnionitis (CA);

OR 8.9, 95% CI 1.9, 40 for histology CA]). In addition, the association between chorioamnionitis and cerebral palsy was demonstrated using meta-analysis. Also, an association between CA and both CP [relative risk (RR) 1.9; 95% CI 1.5, 2.5] and cystic periventricular leukomalacia (cPVL) (RR 2.6; 95% CI 1.7, 3.9) was reported (for excellent review see [5]). It was estimated that up to 12% of spastic CP could be due to intrauterine infection and inflammation [6].

There are specific periods in brain growth during which the developing neurons are particularly susceptible to growth restriction and could be affected by various environmental agents including intrauterine infection during pregnancy. It is suggested that the periods which could be considered as "critical" in brain development is when cells undergo mitosis (the main cells to be discussed are neurons and glia) and also the correct and orderly sequence of cellular migration and the formation of an appropriate histological micro-architecture [7]. Although proliferation and differentiation of astrocytes in rats occurs mainly during postnatal brain development [8], the presence of radial glia (precursors of astrocytes) were also demonstrated in rat fetal brain at embryonic day 15; from this day the expression of astrocyte-specific protein (GFAP) was demonstrated in glial cells [9]. In addition, the presence of microglia in the fetal rat brain was demonstrated at the embryonic day 17 or 18 [10].

Several studies have shown a link between intrauterine infection and cerebral white matter lesions or cerebral palsy in preterm neonates [11-13]. Inflammatory responses may directly affect the immature brain, in addition to neuronal damage after cerebral ischemia. It was shown that the incidence of immature babies, suffering from periventricular leukomalacia (PVL), was significantly increased after chorioamnionitis [14-16]. In endotoxin-mediated leukoencephalopathy in full-term kittens, the cerebral damage occurred during the postnatal period (2-20 day-old of life) [17] and in neonatal dogs, of 1-10 days old, with marked inflammatory infiltrates [18]. More recently, it was reported that ascending intrauterine infection with *E. Coli* caused fetal white matter damage in rabbits; these lesions were observed in 6% of live fetus [19,20].

Astrocytes and microglia, which are the major glial cells in the CNS, are involved in the regulation of the viability, function and differentiation of progenitor cells under physiological conditions. However, they also mediate cytotoxic effect on oligodendrocytes under pathological conditions, by production of pro-inflammatory cytokines [4]. Glia cells are responsible for the deposition of myelin in the CNS during development [21]. Damage of these cells could result in an inadequate amount of myelin and/

or abnormal myelin. Therefore, patients suffering from PVL develop cerebral palsy and impaired cognition during development [22]. It was demonstrated that progenitor oligodendrocytes are more sensitive to cytokine-induced apoptosis than mature oligodendrocytes [23]. Therefore, pathological conditions, such as maternal infection/inflammation may damage progenitor cells or disturb their maturation, and thus affect brain development [2,4].

Mechanisms of brain damage

Intrauterine infection was suggested to affect the immature brains by leading to cerebral hypoperfusion, which may result in a hypoxic-ischemic brain damage, and/or by inducing the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α), interleukin (IL)-1 and IL-6 from astrocytes and microglia. These cytokines could damage oligodendrocyte progenitors and thus induce PVL [2]. Also, upregulation of arachidonic acid metabolism in brain tissue, or activated leukocytes after ischemia may induce the production of oxygen radicals [24]. The effect of these molecules in neuronal cell damage, neurogenesis and neurodifferentiation, in the developing brain has been demonstrated [25,26].

PVL is a predominant form of brain white matter lesion in preterm infants [4]. It is characterized by small and multifocal regions of necrosis [27]. Astroglia and myelin are important components of the white matter. Inflammation of the CNS is characterized by reactive astrogliosis, typified by astrocyte proliferation or astrocytic hypertrophy [28]. These features are under regulation of pro-inflammatory cytokines [29]. In addition, it was shown that occurrence of PVL is associated with increased number of astrocytes in the white matter lesion of infant brains [30].

The origin of the high levels of the pro-inflammatory cytokines in the fetal brain could be the maternal uterus and placenta, following intrauterine infection/inflammation, and/or the stimulated fetal brain microglia and astrocytes [15,31]. It should be emphasized that not all the elevated cytokines in the maternal uterus and placenta are also elevated in the fetal brain.

Systemic maternal administration of lipopolysaccharide (LPS) affected the myelination and astrogliosis in the neonatal rat brain [32]. In addition, IL-1, at physiological doses, inhibited normal rat oligodendrocytes [33,34]. IL-1 stimulates astrocytes growth and increases the appearance of GFAP-reactive astrocytes [34,35]. These observations may suggest a potential role of cytokines in mediating maternal infection and PVL injury in newborn infants.

The expression of IL-1 β and TNF- α mRNA was elevated, in the fetal brain, following maternal LPS administration. In




Figure 1
Possible mechanisms involved in the effect of intrauterine infection during pregnancy and offspring brain damage and development.

addition, the glial fibrillary acidic protein-positive astrocytes levels were increased and the myelin basic protein levels were decreased in the brains of offspring [32]. It was suggested that maternal or placental infection might induce neonatal brain damage by increasing the pro-inflammatory cytokines levels [15]. Recently, higher levels of TNF- α , IL-1 and IL-6 were detected in brains with PVL than in healthy [36]. In addition, it was observed that newborns with brains white matter lesions belonged to mothers with high levels of pro-inflammatory cytokines in the amniotic fluid (AF), however newborns without white matter lesions belonged to mother with normal levels of the examined cytokines [37]. In addition, induced intrauterine infection of rabbits, with bacteria, leads to fetal brain white matter lesions [20].

TNF- α has been shown to increase permeability [38] and to cross the blood-brain barrier [39]. It also reduces cerebral oxygen uptake, increases intracranial pressure [40], induces diffuse intravascular coagulopathy, and increases capillary permeability resulting in cerebral edema [41]. TNF- α is considered a potent cytotoxic agent in neuronal tissue [42]. Expression of TNF- α was demonstrated in brains of developing fetuses after an inflammatory stimulation, and in autopsy specimens of children with PVL [43]. TNF- α was shown to decrease the number of oligodendrocyte progenitors, also causing apoptosis of oligodendrocytes [43-45]. Incubation of hippocampal slices, from mature fetal guinea pig, with LPS increased their capacity to secrete TNF- α . It was suggested that the released TNF- α in these slices might induce apoptotic processes in oligodendrocytes and their progenitors [31,46]. In addition, the combined application of TNF- α and interferon- γ severely reduced survival and inhibited differentiation of oligodendrocyte progenitors in primary culture prepared from neonatal rats, thus may underlie the disrupted myelination that characterizes PVL [12]. Also, higher levels of B-lymphocyte chemoattractant, ciliary neurotrophic factor (CNTF), epidermal growth factors, IL-12, IL-15, monocyte chemoattractant protein-3 and others were demonstrated in sera of children with CP [47].

Involvement of angiogenic and neurotrophic factors in brain development

Neurotrophic factors are a family of proteins, which are involved in the regulation of cell survival and programmed neuronal cell death during development [48]. The capacity of various neurotrophic factors to affect neurons is often developmentally regulated [49]. Some of these factors including brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF) [50,51] were demonstrated as neuroprotective in experimental models of hypoxia-ischemia. The levels of BDNF were decreased in CA1 neurons of the hippocampus, following hypoxia-

ischemia; this was followed by onset of DNA fragmentation and subsequent neuronal death. On the other hand, most of the BDNF-immunopositive neurons did not undergo apoptosis after hypoxia-ischemia [52]. Astrocytes are known to release neurotrophic factors such as platelet-derived growth factor (PDGF), CNTF, BDNF, neurotrophins (NT)-3 and NT-4 [53,54], all of which have been reported to support proliferation and survival of oligodendrocyte progenitor cells [55,56]. LPS was shown to disturb the development of these cells, or even to be cytotoxic, by inducing astrocytes or microglia to produce pro-inflammatory factors such as TNF- α , IL-1 β , IL-6 and nitric oxide (NO). In addition, LPS could induce cytotoxicity by suppressing the production of neurotrophic factors by astrocytes [4].

The process of angiogenesis drives maturation and elaboration of the primary vascular network via proliferation and migration of endothelial cells [57]. Vascular endothelial growth factor (VEGF), is a polypeptide growth factor, which acts as an endothelial cell survival factor and a vascular permeability factor [58]. In addition, VEGF regulate angiogenesis when acting in combination with other factors such as angiopoietin (Ang)-1 and -2 [59]. Although several growth factors and cytokines influence the expression of VEGF, tissue hypoxia is suggested as the major stimulating factor for the upregulation of VEGF in vivo [60].

Endothelin-1 (ET-1) is one of the most potent vasoconstrictors known [61]. ET-1 is a mitogenic [62] and anti-apoptotic factor [63] in many cell types including endothelial cells and astrocytes. Within the CNS, ET-1 was demonstrated in various neuronal groups [64,65] and in glial cells under pathological conditions [66]. Under ischemia and Alzheimer's disease, ET-like immunoreactivity has been detected in astrocytes [67,68]. ET-1 was suggested to play a key role in the development of cerebral vasospasm [69]. Proinflammatory cytokines such as IL-1, TNF- α and transforming growth factor- β , which are produced during endotoxemia, are also increased the production of ET-1 from endothelial cells [12]. Thus, it is possible to suggest that ET could be one of the autocrine/paracrine factors in the different brain regions of the fetus that should be considered under intrauterine infection.

Nitric oxide (NO) plays an important role in the pathogenesis of neuronal injury during cerebral ischemia. NO is the product of enzymatic activity of the constitutive endothelial NO synthase (eNOS), neuronal (nNOS) and inducible (iNOS) isoforms of this enzyme. After ischemia, NO was associated with cerebral vasodilatation (via inducing eNOS activity), and inhibition of platelet aggregation and leukocyte adhesion (via activation of nNOS in neurons and iNOS in microglia and astrocytes) [70,71].

During development, the expression of nNOS parallels that of the glutamate receptor and corresponds to regions of selective vulnerability to hypoxia-ischemia [70,71]. Destruction of neurons containing nNOS in the neonatal rat prior to hypoxia-ischemia lowered the injury score and the frank infarction in the cortex [70,71]. In addition, neonatal mice with targeted destruction of the nNOS gene were markedly protected from injury to neurons in hippocampus and cortex, when also subjected to hypoxia-ischemia insult. The influx of intracellular calcium is increased during cerebral ischemia, and results in activation of nitric oxide-synthase (NOS) and the production NO. NO, like free iron, can increase the toxicity of superoxide radicals, and thus cause neuronal cell damage [70-72].

Apoptosis in the developed brain (under normal physiological conditions) is believed to occur mostly during prenatal development, decline early post-natally and to be minimal in adult brain [71,72]. Ischemia and many other acute and chronic neurodegenerative processes trigger apoptosis [70,71]. Regulation of caspase-3 by BDNF was demonstrated in the neuronal cell bodies and in the striatum and hippocampus following hypoxia-ischemia [83]. Also, upregulation of CD95 (FasL) (the cell surface receptor which induces apoptotic death) was demonstrated in the hippocampus, and thalamus following hypoxia-ischemia injury to the developing rat brain [70,71,74].

The neuropeptides alpha-melanocyte-stimulating hormone (α -MSH) is a proopiomelanocortin derivative that show anti-inflammatory effect within the brain. It regulates and mediates the communication between nervous, endocrine and immune system. It is produced by pituitary cells, neurons, keratinocytes and macrophages [75]. The anti-inflammatory activity of α -MSH was demonstrated in different disease including endotoxemia/ischemia [75-77]. The anti-inflammatory activity of α -MSH include suppression of inflammatory cytokine expression such as TNF- α , interferon- γ , IL-1, IL-6 and IL-8, and also the inhibition of inflammatory activity of neutrophils and monocytes [75,77]. It also blocked LPS-induced expression of TNF- α [78]. In addition, α -MSH was upregulated the anti-inflammatory cytokine IL-10 [79]. Recently, it was demonstrated that α -MSH levels were decreased in plasma of patients with acute brain injury; these levels were in a negative correlation with TNF- α levels [80]. It was also shown that α -MSH acts directly within the brain (through microglia) to modulate local inflammation [81]. Alpha-MSH was demonstrated to inhibit brain tumor necrosis factor-alpha (TNF-alpha), which is involved in human neurodegenerative diseases, induced by local injection of lipopolysaccharide. Ischemia/reperfusion of the brain was shown to induce inflammation in the CNS, and application of α -MSH (systemically) modulated this process. It was dem-

onstrated that such influences of the peptide may occur through inhibition of inflammatory agents produced by glia. Alpha-MSH modulated TNF-alpha and nitric oxide produced by activated murine microglia, and TNF-alpha produced by human astrocytes. Since glial cells can secrete and react to alpha-MSH, it is suggested that these cells act as autocrine regulatory element, which can regulate both fever and inflammation in the brain [82-84].

Thus, it is possible to suggest that α -MSH could be involved in the regulation of the inflammatory processes in the fetal brains of mothers with intrauterine infection, and to be suggested as a possible treatment of CNS disorders that have an inflammatory component.

The involvement of the above factors and mechanisms in the pathophysiology of intrauterine infection during pregnancy and offspring brain damage and development is not yet clear.

Maternal infection/inflammation and offspring development

The association between systemic perinatal infection and cognitive limitations among preterm infants is not yet clear. It has been shown that intrauterine infection and the fetal inflammatory response are associated with an increased risk of preterm birth, which in turn is associated with poor cognitive and perceptual outcome of the preterm newborn [85]. Therefore, it is suggested that intrauterine infection can impair brain development in a manner that may also affect cognitive ability. Cerebral white matter is most closely associated with long-term neuromotor, cognitive, and behavioral limitations in preterm infants [97]. Nevertheless, some infants exposed to perinatal infection, which do not develop white matter damage, might suffer immaturity-related neuronal damage, neuronal disorganization, and excessive neuronal-programmed cell death, abnormal synaptogenesis, dendritic simplification, and abnormalities in neurotransmitters [85].

In addition, it was shown that exposure of animals to products of infection/inflammation induced cognitive deficits. In Wistar rats, the exposure to pyrogens, including LPS and IL-1 β , interrupted task acquisition when administered during the learning process, but not thereafter [85,86]. Since the biomolecular signals regulated by inflammatory cytokines and leading to behavioral abnormalities are not yet clear, it is suggested that interruption of the proinflammatory cytokine cascade might prevent brain damage and impaired development.

Therapeutic possibilities

The relationship between brain damages of offspring following maternal infection/inflammation during

pregnancy is not yet clear. Therefore, some of the suggested therapeutic possibilities are based on possible mechanisms of the offspring brain damages.

Since maternal infection/inflammation increases offspring brain cytokines, which may lead to a cascade of events (as described previously), that could injure the offspring's brains, it is possible to suggest anti-inflammatory cytokines and/or specific inhibitors of intracellular event such as free radical synthesis or scavengers, NOS inhibitors and/or scavengers and anti apoptotic agents as possible prevention/therapeutic agents.

Possible therapeutic interventions may also include supplementation of trophic factors, which may increase survival and differentiation of oligodendrocyte precursors, as well as anti-inflammatory agents.

It should be emphasized that other mechanism such as increased maternal temperature, placental endothelial damage and increased coagulation tendency, fetal hypoxia or acidosis, fetal hypotension and others may also aggravate fetal brain damage. In addition, we did not consider, in this review, the viral infections which also could result in brain damage.

In summary, it is possible to hypothesize that intrauterine infection/inflammation during pregnancy may lead to newborn, adult and aged offspring brain damages (Fig. 1). This may affect morphogenic and behavioral phenotypes of the developed offspring. The offspring brain damage could be mediated through up-regulation of pro-inflammatory cytokine production in the circulation and in the brain of the fetal/offspring. These pro-inflammatory cytokines could, by one hand, decrease the production of neurotrophic factors such as NGF and BDNF and, by other hand, to increase the production of NO, VEGF and PGE. These factors increase apoptosis and also may lead to vascularization/angiogenesis defects. Affecting these functions in the brain may lead to compartment/site brain damage, which may, during a developmental window, lead to some neurological diseases and/or cognitive defects.

References

- Volpe JJ: **Perinatal brain injury: from pathogenesis to neuroprotection.** *Ment Retard Devel Disab Res Rev* 2001, **7**:56-64.
- Berger R, Garnier Y, Jensen A: **Perinatal brain damage: underlying mechanisms and neuroprotective strategies.** *J Soc Gynecol Investig* 2002, **9**:319-328.
- Wu YW, Colford JM Jr: **Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis.** *JAMA* 2000, **284**:1417-1424.
- Pang Y, Cai Z, Rhodes PG: **Effects of lipopolysaccharide on oligodendrocyte progenitor cells are mediated by astrocytes and microglia.** *J Neurosci Res* 2000, **62**:510-520.
- Garnier Y, Coumans ABC, Jensen A, Hassart THM, Berger R: **Infection-related perinatal brain injury: the pathogenic role of impaired fetal cardiovascular control.** *J Soc Gynecol Investing* 2003, **10**:450-459.
- Schendel D, Schuchat A, Thorsen P: **Public health issues related to infection and pregnancy and cerebral palsy.** *Ment Retard Dev Disabil Res Rev* 2002, **8**:39-45.
- Nyakas C, Buwalda B, Luiten PGM: **Hypoxia and brain development.** *Prog Neurobiol* 1996, **49**:1-51.
- Rickmann M, Wolff JR: **Prenatal oligogenesis in the neopallium of the rat.** *Adv Anat Embryol Cell Biol* 1985, **93**:1-10.
- Sancho-Tello M, Valles S, Montoliu C, Renau-Piqueras J, Guerri C: **Developmental pattern of GFAP and vimentin gene expression in rat brain and radial glial cultures.** *Glia* 1995, **15**:157-166.
- Chamak B, Dobbertin A, Mallat M: **Immunohistochemical detection of thrombospondin in microglia in the developing rat brain.** *Neuroscience* 1995, **69**:177-187.
- Murphy DJ, Sellers S, MacKenzie IZ, Yudkin PL, Johnson AM: **Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies.** *Lancet* 1995, **346**:1449-1454.
- Zupan V, Gonzales P, Lacaze-Masmonteil T, Boithias C, d'Allest AM, Dehan M, Gabilan JC: **Periventricular leukomalacia: risk factors revisited.** *Dev Med Child Neurol* 1996, **38**:1061-1067.
- Verma U, Tejani N, Klein S, Reale MR, Beneck D, Figueroa R, Visintainer P: **Obstetric antecedents of intraventricular hemorrhage and periventricular leukomalacia in the low-birth-weight neonate.** *Am J Obstet Gynecol* 1997, **176**:275-281.
- Berger R, Bender S, Sefkow S, Klingmüller V, Künzel W, Jensen A: **Periventricular haemorrhage: A cranial ultrasound study on 5286 neonates.** *Eur J Obstet Gynecol Reprod Biol* 1997, **75**:191-203.
- Dammann O, Leviton A: **Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn.** *Pediatr Res* 1997, **42**:1-8.
- Yoon BH, Romero R, Park JS, Kim CJ, Kim SH, Choi JH, Han TR: **Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years.** *Am J Obstet Gynecol* 2000, **182**:675-681.
- Gilles FH, Leviton A, Kerr CS: **Endotoxin leucoencephalopathy in the telencephalon of the newborn kitten.** *J Neurol Sci* 1976, **27**:183-191.
- Young RS, Yagel SK, Towfighi J: **Systemic and neuropathologic effects of E. coli endotoxin in neonatal dogs.** *Pediatr Res* 1983, **17**:349-353.
- Debillon T, Gras-Leguen C, Verielle V, Winer N, Caillon J, Roze J-C, Gressens P: **Interauterine infection induces programmed cell death in rabbit periventricular white matter.** *Pediatr Res* 2000, **47**:736-742.
- Yoon BH, Kim CJ, Romero R, Jun JK, Park KH, Choi ST, Chi JG: **Experimentally induced intrauterine infection causes fetal brain white matter lesions in rabbits.** *Am J Obstet Gynecol* 1997, **177**:797-802.
- Bunge RP: **Glial cells and the central myelin sheath.** *Physiol Rev* 1968, **48**:197-251.
- Jacobson L, Ek U, Fernell E, Flodmark O, Broberger U: **Visual impairment in preterm children with periventricular leukomalacia-visual, cognitive and neuropsychiatric characteristics related to cerebral imaging.** *Dev Med Child Neurol* 1996, **38**:724-735.
- Baerwald KD, Popko B: **Developing and mature oligodendrocytes respond differently to immune cytokine interferon- γ .** *J Neurosci Res* 1998, **52**:230-239.
- Helfaer MA, Kirsch JR, Traystman RJ: **Radical scavengers: Penetration into brain following ischemia and reperfusion.** In: *Pharmacology of cerebral ischemia* Edited by: Kriegstein J, Oberpichler-Schwenk H. Medpharm Scientific, Stuttgart; 1994:297-309.
- Palmer C, Towfighi J, Roberts RL, Heitjan DF: **Allopurinol administered after inducing hypoxia/ischemia reduces brain injury in 7-day-old rats.** *Pediatr Res* 1993, **33**:405-411.
- Saito K, Packianathan S, Longo LD: **Free radical-induced elevation of ornithine decarboxylase activity in developing rat brain slices.** *Brain Res* 1997, **763**:232-238.
- Banker BQ, Larroche JC: **Periventricular leukomalacia of infancy. A form of neonatal anoxic encephalopathy.** *Arch Neurol* 1962, **7**:386-610.
- Maxwell WL, Follows R, Ashhurst DE, Berry M: **The response of the cerebral hemisphere of the rat to injury: I. The mature rat.** *Philos Trans R Soc Lond Biol Sci* 1990, **328**:479-500.

29. Balasingam V, Tejada-Berges T, Wright E, Bouchova R, Yong VW: **Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines.** *J Neurosci* 1994, **14**:846-856.
30. Deguchi K, Oguchi K, Takashima S: **Characteristic neuropathology of leukomalacia in extremely low birth weight infants.** *Pediatr Neurol* 1997, **16**:296-300.
31. Feldhaus B, Dietzel ID, Berger R: **TNF- α induces cell death in primary cultures of oligodendrocyte progenitors.** *J Soc Gynecol Investig* 2001, **8**:248A.
32. Cai Z, Pan ZO, Pang Y, Evans OB, Rhodes PG: **Cytokine induction in fetal rat brains and brain injury in neonatal rats after maternal lipopolysaccharide administration.** *Pediatr Res* 2000, **47**:64-72.
33. Merrill JE: **Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological.** *Dev Neurosci* 1992, **14**:1-10.
34. Merrill JE: **The effects of IL-1 and TNF alpha on astrocytes, microglia, oligodendrocytes and glial precursors in vitro.** *Dev Neurosci* 1991, **13**:130-137.
35. Giulian D, Young DG, Woodward J, Brown DC, Lachman LB: **Interleukin-1 is an astroglial growth factor in developing nervous system.** *J Neurosci* 1988, **8**:709-714.
36. Yoon BH, Romero R, Kim CJ, Koo JN, Choe G, Syn HC, Chi JG: **High expression of tumor necrosis factor- α and interleukin-6 in periventricular leukomalacia.** *Am J Obstet Gynecol* 1997, **177**:406-411.
37. Yoon BH, Jun JK, Romero R, Park KH, Gomez R, Choi J-H, Kim I-O: **Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1 β , and tumor necrosis factor- α), neonatal brain white matter lesions, and cerebral palsy.** *Am J Obstet Gynecol* 1997, **177**:19-26.
38. Megyeri P, Abraham CS, Temesvari P, Kovacs J, Vas T, Speer CP: **Recombinant human tumor necrosis factor alpha constricts pial arterioles and increases blood-brain barrier permeability in newborn piglets.** *Neurosci Lett* 1992, **148**:137-140.
39. Uno H, Matsuyama T, Akita H, Nishimura H, Sugita M: **Induction of tumor necrosis factor- α in the mouse hippocampus following transient forebrain ischemia.** *J Cereb Blood Flow Metab* 1997, **17**:491-499.
40. Tureen J: **Effect of recombinant human tumor necrosis factor- α on cerebral oxygen uptake, cerebrospinal fluid lactate, and cerebral blood flow in the rabbit: Role of nitric oxide.** *J Clin Invest* 1995, **95**:1086-1091.
41. Duchini A, Govindarajan S, Santucci M, Zampi G, Hofman FM: **Effects of tumor necrosis factor- α and interleukin-6 on fluid-phase permeability and ammonia diffusion in CNS-derived endothelial cells.** *J Invest Med* 1996, **44**:474-482.
42. Botchkina GI, Geimonen E, Bilof ML, Villarreal O, Tracey KJ: **Loss of NF- κ B activity during cerebral ischemia and TNF cytotoxicity.** *Mol Med* 1999, **5**:372-381.
43. Bell MJ, Hallenbeck JM: **Effects of intrauterine inflammation on developing rat brain.** *J Neurosci Res* 2002, **70**:570-579.
44. Cammer W: **Effects of TNF- α on immature and mature oligodendrocytes and their progenitors in vitro.** *Brain Res* 2000, **864**:213-219.
45. Ladiwala U, Hewei L, Antel J, Nalbantoglu J: **p53 induction by tumor necrosis factor- α and involvement of p53 in cell death of human oligodendrocytes.** *J Neurochem* 1999, **73**:605-611.
46. Berger R, Garnier Y, Pfeiffer D, Jensen A: **Lipopolysaccharides do not alter metabolic disturbances in hippocampal slices of fetal guinea pigs after oxygen-glucose deprivation.** *Pediatr Res* 2000, **48**:531-535.
47. Kaukola T, Satyaraj E, Patel DD, Tchernev VT, Grimwade BG, Kingsmore SF, Koskela P, Vainionpaa L, Pihko H, Aarimaa T, Hallman M: **Cerebral palsy is characterized by protein mediators in cord serum.** *Ann Neurol* 2004, **55**:186-194.
48. Oppenheim RW, Prevette D, Yin QW: **Control of embryonic motoneuron survival in vivo by ciliary neurotrophic factor.** *Science* 1991, **251**:1616-1618.
49. Knusel B, Rabin SJ, Hefti F: **Regulated neurotrophin receptor responsiveness during neuronal migration and early differentiation.** *J Neurosci* 1994, **14**:1542-1554.
50. Han BH, Holtzman DM: **BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway.** *J Neurosci* 2000, **20**:5775-5781.
51. Kirschner PB, Jenkins BG, Schulz JB: **NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals.** *Brain Res* 1996, **713**:178-185.
52. Walton M, Connor B, Lawlor P, Young D, Sirimanne E, Gluckman P, Cole G, Dragunow M: **Neuronal death and survival in two models of hypoxic-ischemic brain damage.** *Brain Res Brain Res Rev* 1999, **29**:137-168.
53. Schwartz JP, Nishiyama N: **Neurotrophic factor gene expression in astrocytes during development and following injury.** *Brain Res Bull* 1994, **35**:403-407.
54. Kamiguchi H, Yoshida K, Sagoh M, Sasaki H, Inaba M, Wakamoto H, Otani M, Toya S: **Release of ciliary neurotrophic factor from cultured astrocytes and its modulation by cytokines.** *Neurochem Res* 1995, **20**:1187-1193.
55. Kahn MA, de Vellis J: **Growth factors in the CNS and their effects on oligodendroglia.** *Prog Brain Res* 1995, **105**:145-169.
56. Heinrich M, Gorath M, Landsberg CR: **Neurotrophin-3(NT-3) modulates early differentiation of oligodendrocytes in rat brain cortical culture.** *Glia* 1999, **28**:244-255.
57. Patan S: **Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling.** *J Neurooncol* 2000, **50**:1-15.
58. Miquerol L, Langille BL, Nagy A: **Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression.** *Development* 2000, **127**:3941-3946.
59. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: **Vascular-specific growth factors and blood vessel formation.** *Nature* 2000, **407**:242-248.
60. Taylor CM, Stevens H, Anthony FW, Wheeler T: **Influence of hypoxia on vascular endothelial growth factor-derived cell lines: JEG, Jar and BeWo.** *Placenta* 1997, **18**:451-458.
61. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: **A novel potent vasoconstrictor peptide produced by vascular endothelial cells.** *Nature* 1988, **332**:411-415.
62. Hirata Y, Takagi Y, Fukuda Y, Marumo F: **Endothelin is a potent mitogen for rat vascular smooth muscle cells.** *Atherosclerosis* 1989, **78**:225-228.
63. Shichiri M, Marumo F, Hirata Y: **Endothelin-B receptor-mediated suppression of endothelial apoptosis.** *J Cardiovasc Pharmacol* 1998, **31**:S138-S141.
64. Lee ME, de la Monte SM, Ng SC, Bloch KD, Quertermous T: **Expression of the potent vasoconstrictor endothelin in the human central nervous system.** *J Clin Invest* 1990, **86**:141-147.
65. Nakamura S, Naruse M, Naruse K, Shioda S, Nakai Y, Uemura H: **Colocalization of immunoreactive endothelin-1 and neurohypophysial hormones in the axons of the neural lobe of the rat pituitary.** *Endocrinology* 1993, **132**:530-533.
66. Kuwaki T, Kurihara H, Cao WH, Kurihara Y, Unekawa M, Yazaki Y, Kumada M: **Physiological role of brain endothelin in the central autonomic control: from neuron to knockout mouse.** *Prog Neurobiol* 1997, **51**:545-579.
67. Yamashita K, Kataoka Y, Yamashita YS, Himeno A, Tsutsumi K, Niwa M, Taniyama K: **Glial endothelin/nitric oxide system participates in hippocampus CA1 neuronal death of SHRSP following transient forebrain ischaemia.** *Clin Exp Pharmacol Physiol* 1995, **22**:S277-S278.
68. Zhang WW, Badonic T, Hoog A, Jiang MH, Ma KC, Nie XJ, Olsson Y: **Astrocytes in Alzheimer's disease express immunoreactivity to the vasoconstrictor endothelin-1.** *J Neurol Sci* 1994, **122**:90-96.
69. Josko J: **Cerebral angiogenesis and expression of VEGF after subarachnoid hemorrhage (SAH) in rats.** *Brain Res* 2003, **981**:58-69.
70. Dirnagl D, Iadecola C, Moskowitz MA: **Pathobiology of ischaemic stroke: an integrated view.** *Trends Neurosci* 1999, **22**:391-397.
71. Vexler ZS, Ferriero DM: **Molecular and biochemical mechanisms of perinatal brain injury.** *Semin Neonatol* 2001, **6**:99-108.
72. Marks N, Berg MJ: **Recent advances on neuronal caspases in development and neurodegeneration.** *Neurochem Int* 1999, **35**:195-220.
73. Han BH, D'Costa A, Back SA, Parsadanian M, Shah AR, Gidday JM, Srinivasan A, Deshmukh M, Holtzman DM: **BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia.** *Neurobiol Dis* 2000, **7**:38-53.

74. Felderhoff-Mueser U, Taylor DL, Greenwood K, Kozma M, Stibenz D, Joashi UC, Edwards AD, Mehmet H: **Fas/CD95/APO-1 can function as a death receptor for neuronal cells in vitro and in vivo and is upregulated following cerebral hypoxic-ischemic injury to the developing rat brain.** *Brain Pathol* 2000, **10**:17-29.
75. Lipton JM, Catania A: **Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH.** *Immunol Today* 1997, **18**:140-145.
76. Oktar BK, Ercan F, Yegen BC, Alican I: **The effect of alpha-melanocyte stimulating hormone on colonic inflammation in the rat.** *Peptides* 2000, **21**:1271-1277.
77. Rajora N, Boccoli G, Catania A, Lipton JM: **alpha-MSH modulates experimental inflammatory bowel disease.** *Peptides* 1997, **18**:381-385.
78. Taherzadeh S, Sharma S, Chhajlani V, Gantz I, Rajora N, Demitri MT, Kelly L, Zhao H, Ichiyama T, Catania A, Lipton JM: **alpha-MSH and its receptors in regulation of tumor necrosis factor-alpha production by human monocyte/macrophages.** *Am J Physiol* 1999, **276**:R1289-1294.
79. Redondo P, Garcia-Foncillas J, Okroujnov I, Bandres E: **Alpha-MSH regulates interleukin-10 expression by human keratinocytes.** *Arch Dermatol Res* 1998, **290**:425-428.
80. Magnoni S, Stocchetti N, Colombo G, Carlin A, Colombo A, Lipton JM, Catania A: **Alpha-melanocyte-stimulating hormone is decreased in plasma of patients with acute brain injury.** *J Neurotrauma* 2003, **20**:251-260.
81. Lipton JM, Catania A, Delgado R: **Peptide modulation of inflammatory processes Peptide modulation of inflammatory processes within the brain.** *Neuroimmunomodulation* 1998, **5**:178-83.
82. Catania A, Lipton JM: **Peptide modulation of fever and inflammation within the brain.** *Ann N Y Acad Sci* 1998, **856**:62-68.
83. Lipton JM, Catania A: **Mechanisms of antiinflammatory action of the neuroimmunomodulatory peptide alpha-MSH.** *Ann N Y Acad Sci* 1998, **1**:373-380.
84. Wong KY, Rajora N, Boccoli G, Catania A, Lipton JM: **A potential mechanism of local anti-inflammatory action of alpha-melanocyte-stimulating hormone within the brain: modulation of tumor necrosis factor-alpha production by human astrocytic cells.** *Neuroimmunomodulation* 1997, **4**:37-41.
85. Dammann O, Kuban KCK, Leviton A: **Perinatal infection, fetal inflammatory response, white matter damage, and cognitive limitation in children born preterm.** *Ment Retard Dev Disabil Res Rev* 2002, **8**:46-50.
86. Aubert A, Vega C, Dantzer R, Goodall G: **Pyrogens specifically disrupt the acquisition of a task involving cognitive processing in the rat.** *Brain Behav Immun* 1995, **9**:129-148.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

